RxDoctor Payments Data

Beatris Ther Hacopian, MD

Family Medicine · Los Angeles, CANPI 1952460552

Payments from drug & device makers

$1,429in general payments, 2019–2025

Across 63 payments — averaging $22.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$383
  • Lilly USA, LLC$245
  • Intuitive Surgical$110
  • Bayer$101
  • Amgen$57
  • Lexicon Pharmaceuticals, Inc.$54
  • plus $480 from 16 others

What the payments were for

  • Food & beverage$1,429100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,429 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$30,881
Medicare patients
121
Services billed
329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin43$46,311
JanuviaSitagliptin Phosphate17$13,782
EliquisApixaban18$11,513
Diclofenac Sodium50$9,842
Atorvastatin Calcium271$2,246
Rosuvastatin Calcium116$1,542
Losartan Potassium132$1,484
SynthroidLevothyroxine Sodium23$1,460
Levothyroxine Sodium106$1,447
Amlodipine Besylate229$1,423
Olmesartan Medoxomil78$1,378
Metoprolol Succinate63$1,002
Albuterol Sulfate HfaAlbuterol Sulfate33$862
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide41$813
Propranolol Hcl28$642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$383$46,31143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →